381 related articles for article (PubMed ID: 32286543)
1. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
[No Abstract] [Full Text] [Related]
2. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
3. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
4. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
[TBL] [Abstract][Full Text] [Related]
7. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
9. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
10. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
11. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Vigna E; Martino EA; Mendicino F; Botta C; Caracciolo D; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 May; 96(5):E168-E171. PubMed ID: 33580969
[No Abstract] [Full Text] [Related]
13. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
14. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Michallet AS; Letestu R; Le Garff-Tavernier M; Aanei C; Ticchioni M; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; De Guibert S; Orsini Piocelle F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan-Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Levy V; Nguyen-Khac F; Feugier P
Blood; 2021 Feb; 137(8):1019-1023. PubMed ID: 33167024
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
Timofeeva N; Gandhi V
Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
[TBL] [Abstract][Full Text] [Related]
17. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
18. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
[TBL] [Abstract][Full Text] [Related]
19. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
[No Abstract] [Full Text] [Related]
20. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
